TY - JOUR
T1 - World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Eating Disorders
AU - Aigner, Martin
AU - Treasure, Janet
AU - Kaye, Walter
AU - Kasper, Siegfried
AU - Bailer, Ursula
AU - Brambilla, Francesca
AU - Bulik, Cynthia
AU - Athanasios Cordas, Taki
AU - Dardennes, Roland
AU - De Zwaan, Martina
AU - Fernandez-Aranda, Fernando
AU - Fetissov, Serguei
AU - Fichter, Manfred
AU - Halmi, Katherine
AU - Hoek, Hans
AU - Karwautz, Andreas
AU - Kiriike, Nobuo
AU - Lopez-Mato, Andrea
AU - Mendonca Vilela, Joao Eduardo
AU - Mitchell, James
AU - Monteleone, Palmiero
AU - Papezova, Hana
AU - Råstam, Maria
AU - Rihmer, Zoltan
AU - Steiger, Howard
AU - Stein, Daniel
AU - Udristoiu, Tudor
AU - Zechowski, Cezary
PY - 2011
Y1 - 2011
N2 - Objectives. The treatment of eating disorders is a complex process that relies not only on the use of psychotropic drugs but should include also nutritional counselling, psychotherapy and the treatment of the medical complications, where they are present. In this review recommendations for the pharmacological treatment of eating disorders (anorexia nervosa (AN), bulimia nervosa (BN), binge eating disorder (BED)) are presented, based on the available literature. Methods. The guidelines for the pharmacological treatment of eating disorders are based on studies published between 1977 and 2010. A search of the literature included: anorexia nervosa bulimia nervosa, eating disorder and binge eating disorder. Many compounds have been studied in the therapy of eating disorders (AN: antidepressants (TCA, SSRIs), antipsychotics, antihistaminics, prokinetic agents, zinc, Lithium, naltrexone, human growth hormone, cannabis, clonidine and tube feeding; BN: antidepressants (TCA, SSRIs, RIMA, NRI, other AD), antiepileptics, odansetron, d-fenfluramine Lithium, naltrexone, methylphenidate and light therapy; BED: antidepressants (TCA, SSRIs, SNRIs, NRI), antiepileptics, baclofen, orlistat, d-fenfluramine, naltrexone). Results. In AN 20 randomized controlled trials (RCT) could be identified. For zinc supplementation there is a grade B evidence for AN. For olanzapine there is a category grade B evidence for weight gain. For the other atypical antipsychotics there is grade C evidence. In BN 36 RCT could be identified. For tricyclic antidepressants a grade A evidence exists with a moderate-risk-benefit ratio. For fluoxetine a category grade A evidence exists with a good risk-benefit ratio. For topiramate a grade 2 recommendation can be made. In BED 26 RCT could be identified. For the SSRI sertraline and the antiepileptic topiramate a grade A evidence exists, with different recommendation grades. Conclusions. Additional research is needed for the improvement of the treatment of eating disorders. Especially for anorexia nervosa there is a need for further pharmacological treatment strategies
Read More: http://informahealthcare.com/doi/abs/10.3109/15622975.2011.602720
AB - Objectives. The treatment of eating disorders is a complex process that relies not only on the use of psychotropic drugs but should include also nutritional counselling, psychotherapy and the treatment of the medical complications, where they are present. In this review recommendations for the pharmacological treatment of eating disorders (anorexia nervosa (AN), bulimia nervosa (BN), binge eating disorder (BED)) are presented, based on the available literature. Methods. The guidelines for the pharmacological treatment of eating disorders are based on studies published between 1977 and 2010. A search of the literature included: anorexia nervosa bulimia nervosa, eating disorder and binge eating disorder. Many compounds have been studied in the therapy of eating disorders (AN: antidepressants (TCA, SSRIs), antipsychotics, antihistaminics, prokinetic agents, zinc, Lithium, naltrexone, human growth hormone, cannabis, clonidine and tube feeding; BN: antidepressants (TCA, SSRIs, RIMA, NRI, other AD), antiepileptics, odansetron, d-fenfluramine Lithium, naltrexone, methylphenidate and light therapy; BED: antidepressants (TCA, SSRIs, SNRIs, NRI), antiepileptics, baclofen, orlistat, d-fenfluramine, naltrexone). Results. In AN 20 randomized controlled trials (RCT) could be identified. For zinc supplementation there is a grade B evidence for AN. For olanzapine there is a category grade B evidence for weight gain. For the other atypical antipsychotics there is grade C evidence. In BN 36 RCT could be identified. For tricyclic antidepressants a grade A evidence exists with a moderate-risk-benefit ratio. For fluoxetine a category grade A evidence exists with a good risk-benefit ratio. For topiramate a grade 2 recommendation can be made. In BED 26 RCT could be identified. For the SSRI sertraline and the antiepileptic topiramate a grade A evidence exists, with different recommendation grades. Conclusions. Additional research is needed for the improvement of the treatment of eating disorders. Especially for anorexia nervosa there is a need for further pharmacological treatment strategies
Read More: http://informahealthcare.com/doi/abs/10.3109/15622975.2011.602720
KW - antiepileptics
KW - antipsychotics
KW - antidepressants
KW - pharmacotherapy
KW - Bulimia nervosa
KW - Binge Eating Disorder
KW - Anorexia nervosa
KW - guidelines
KW - eating disorder
KW - drug treatment
KW - antihistaminics
KW - tube feeding
KW - light therapy
U2 - 10.3109/15622975.2011.602720
DO - 10.3109/15622975.2011.602720
M3 - Article
SN - 1562-2975
VL - 12
SP - 400
EP - 443
JO - World Journal of Biological Psychiatry
JF - World Journal of Biological Psychiatry
IS - 6
ER -